(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.53%.
Acurx Pharmaceuticals's earnings in 2025 is -$9,170,053.On average, 5 Wall Street analysts forecast ACXP's earnings for 2025 to be -$12,124,300, with the lowest ACXP earnings forecast at -$11,689,711, and the highest ACXP earnings forecast at -$12,437,105. On average, 5 Wall Street analysts forecast ACXP's earnings for 2026 to be -$8,082,867, with the lowest ACXP earnings forecast at -$9,523,436, and the highest ACXP earnings forecast at -$6,021,486.
In 2027, ACXP is forecast to generate -$7,423,475 in earnings, with the lowest earnings forecast at -$8,481,171 and the highest earnings forecast at -$6,349,930.